The interleukin-10 promoter polymorphism rs1800872 (-592C>A), contributes to cancer susceptibility: meta-analysis of 16,785 cases and 19,713 controls

PLoS One. 2013;8(2):e57246. doi: 10.1371/journal.pone.0057246. Epub 2013 Feb 27.

Abstract

Interleukin-10 (IL-10) is a multifunctional cytokine which participates in the development and progression of various malignant tumors. To date, a number of case-control studies were conducted to detect the association between IL-10-592C>A polymorphism and cancer risk in humans. However, the results of these studies on the association remain conflicting. In an effort to solve this controversy, we performed a meta-analysis based on 70 case-control studies from 65 articles, including 16 785 cancer cases and 19 713 controls. We used odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the association. The overall results suggested that the variant homozygote genotype AA of the IL-10-592C>A polymorphism was associated with a moderately decreased risk of all cancer types (OR = 0.90, 95% CI = 0.83-0.98 for homozygote comparison, OR = 0.92, 95% CI = 0.86-0.98 for recessive model). In the stratified analyses, the risk remained for studies of smoking-related cancer, Asian populations and hospital-based studies. These results suggested that the IL-10-592C>A polymorphism might contribute to the cancer susceptibility, especially in smoking-related cancer, Asians and hospital-based studies. Further studies are needed to confirm the relationship.

Publication types

  • Meta-Analysis

MeSH terms

  • Case-Control Studies
  • Gene Frequency / genetics
  • Genetic Heterogeneity
  • Genetic Predisposition to Disease*
  • Humans
  • Interleukin-10 / genetics*
  • Neoplasms / genetics*
  • Polymorphism, Single Nucleotide / genetics*
  • Promoter Regions, Genetic*
  • Publication Bias
  • Risk Factors

Substances

  • IL10 protein, human
  • Interleukin-10

Grants and funding

These authors have no support or funding to report.